Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System

Published by: NeuroInsights, LLC

Published: May. 18, 2007 - 369 Pages


Table of Contents


01 Executive Summary

The Brain Industry Revealed

Investment Risks and Opportunities

Neurotechnology and Society

Key Industry Facts and Findings

Timeline of Advances in Neuroscience

02 Trends and Drivers

Converging Technologies

Stem Cells and Neuroregeneration

Neuroimaging and Disease Treatment

Crossing the Blood Brain Barrier

Demographic Drivers

More People Living Longer

Social Drivers

The Life Style Improvement Market

Economic Drivers

Worldwide Economic Burden

Rising Healthcare Costs

Research Funding

United States Government

International Research Funding

Foundations Focus on the Brain

Regulatory Trends

International Regulatory Competition

Intellectual Property Trends

Global Intellectual Property Protection

Neuropharmaceutical Patent Expirations

Patent Activity in the US: 1980-2004

Selected Neurotechnology Patents

03 Neuropharmaceutical Sector

Cogniceutical Market

Alzheimer's Disease

Mild Cognitive Impairment

Attention Deficit Disorders

Sleep Disorders

Emoticeutical Market

Depression

Anxiety Disorders

Sensoceutical Market

Chronic Pain

Retinal and Optic Nerve Disorders

Epilepsy and Seizure Disorders

Parkinson's Disease

Other Markets

Schizophrenia and Psychosis

Addiction and Substance Abuse

Obesity

Stroke

04 Neurodevice Sector

Neuroprosthetic Devices

Cochlear Implants

Retinal Implants

Motor Prostheses & Brain-Computer Interface

Neurostimulation Devices

Brain Stimulation

Spinal Cord Stimulation

Vagus Nerve Stimulation

Peripheral Nerve Stimulation

Neurosurgical Devices

Neurosurgical Navigation Equipment

Radiosurgical Devices

Neurovascular Intervention

Neurosoftware

Attention Deficit Disorders

Pain Control

Age-related Disorders

05 Neurodiagnostic Sector

Neuroimaging

Computed Tomography (CT)

Magnetic Resonance Imaging (MRI, fMRI)

Nuclear Medicine Imaging (PET, SPECT)

Electroencephalography (EEG)

Magnetoencephalography (MEG)

In Vitro Diagnostics

Genetic Testing and Pharmacogenomics

Protein Biomarker Assays

Neuroinformatics

Patient Dataset Management

Open Source Software

06 Private Neurotech Investment

U.S. Venture Capital Investment 1999-2004

Neurotech Venture Capital 1999-2004

Largest Neurotech Investments 1999-2004

Leading Neurotech Venture Capital Firms

07 Public Neurotech Investment

Neurotech Initial Public Offerings 2004-Q12006

Neurotech M&A activity

Neuropharma Research and Licensing Deals

NeuroInsights' Neurotech Index

Neurotech Index Performance

08 Leading Research Centers

University of California, San Francisco (UCSF)

Massachusetts Institute of Technology (MIT)

University of California, San Diego (UCSD)

Harvard University

Stanford University

University of California, Los Angeles (UCLA)

Columbia University

University College London (UCL)

Karolinska Institutet, Stockholm

RIKEN Brain Science Institute, Japan

Places to Watch

09 Leading Neurotechnology Regions

The Global Neurotech Economy

Nexus Ranking and Methodology

Establish Neurotech Nexus'

Emerging Neurotech Nexus'

Nascent Neurotech Nexus'

Conclusions and Policy Recommendations

10 Company Profiles

Neuropharmaceutical Companies

Private

Public

Neurodevice Companies

Private

Public

Neurodiagnostic Companies

Private

Public




The Neurotechnology Industry 2007 Report: Exhibits, Tables, and Charts:

1-1: Number of Individuals Afflicted by Indication, US and Worldwide, Top 15 Indications

1-2: Global Pharmaceutical Sales by Indication, 2005

1-3: Neurotechnology Industry Taxonomy

1-4: Proportion of Patient Population Segmented by Neurotech Market Opportunity

1-5: NeuroInsights Neurotech Index Performance vs. S&P500, NASQAQ Composite, and NASDAQ Biotechnology Index

2-1: Projected Percentage Increase in Global Populations aged 65 and over, 1994-2020

2-2: Neuropharmaceutical Patent Expirations and Generic Competition, 2003-2011

2-3: Neurotechnology Patent Approvals, US, 1985-2005

2-4: Neuropharmaceutical Patent Approvals, US, 1985-2005

2-5: Neurodevice Patent Approvals, US, 1985-2005

2-6: Neurodiagnostic Patent Approvals, US, 1985-2005

2-7: Selected US Foundations with a Significant focus on Brain Research and Education

2-8: Most Generous Philanthropists for Medical and Brain Research

2-9: Global Stem Cell Policy Map

3-1: Pharmaceutical Sales in Top 13 World Markets by therapeutic class, 2001-2005

3-2: Neuropharmaceutical Markets, Worldwide Sales in 2005

3-3: Number of people Afflicted and Market Size by Type of Neuropsychiatric Disorder

3-4: Neuropharmaceutical Revenues by Indication in 2004

3-5: FDA Pharmaceutical Approval Process

3-6: Clinical Trials for Alzheimer’s disease (company, compound, phase, mechanism)

3-7: Clinical Trials for Mild Cognitive Impairment (same for all clinical trial tables)

3-8: Clinical Trials for ADHD

3-9: Clinical Trials for Sleep Disorders

3-10: Clinical Trials for Depression

3-11: US Sales of Leading SSRI and SNRIs, 1999-2005

3-12: Clinical Trials for Anxiety disorders

3-13: Clinical Trials for Pain

3-14: US Sales of Leading COX-2 Inhibitors, 1999-2005

3-15: Clinical Trials for Retinal and Optic Nerve Disorders

3-16: Clinical Trials for Epilepsy

3-17: Clinical Trials for Parkinson’s disease

3-18: Clinical Trials for Schizophrenia and Psychosis

3-19: US Sales of Leading Anti-psychotics, 1999-2005

3-20: Clinical Trials for Addition and Substance Abuse

3-21: Clinical Trials for Obesity Treatment

3-22: Clinical Trials for Stroke Treatment

4-1: New Neurodevice FDA Registrations, 1996-2005

4-2: FDA Classification and Approval Process for Medical Devices

4-3: Neurodevice Acquisition and Investment Activity: Medtronic, Boston Scientific, J&J

4-4: Neurodevice Markets (Neuroprosthetic, Neurostimulation, Neurosurgical, Neurofeedback)

4-5: Neurostimulation Device Clinical Trials

5-1: Neurodiagnostics Markets (Neuroimaging, In Vitro Diagnostics, Neuroinformatics)

5-2: FDA Approval and Insurance Reimbursement of Diagnostics

5-3: Neuroimaging Technology (CT, MRI, fMRI, PET, SPECT, EEG, MEG)

5-4: Projected Number of Pharmacogenetic Tests by Indication 2003-2013

5-5: Medical Divisions of Fortune 500 Dominate Neuroimaging Market

5-6: Alzheimer’s Disease Neuroimaging Initiative

5-7: Neuroinformatics Data Storage

5-8: Paul Allen Brain Atlas Project and IBM Blue Brain Project

6-1: Total US Venture Capital Investment, 1999-2005

6-2: US Life Science Venture Capital Investment, 1999-2005

6-3: US Neurotechnology Venture Capital Investment, 1999-2005

6-4: Neurotech as Percent of Life Science Venture Investment, 1999-2005

6-5: Top Five Neurotechnology Venture Capital Financings, 2000-2005

6-6: Top 10 Neurotech Venture Capital Firms with Investments

7-1: Neurotechnology Initial Public Offerings US, 2004-Q1 2006

7-2: Selected Neurotech M&A Activity, 2004-Q1 2006

7-3: Selected Neuropharmaceutical Research and Licensing Deals 2004-Q1 2006

7-4: Neurotech Index Companies 2006

7-2: Neurotech Index Company Fundamentals

7-3: Index Company Performance

8-1 Leading Neurotechnology Research Centers

8-2 Neurotech Research Centers and Affiliated Institutes, Funding, Recent Significant Investments, Reputation, Translation of Discoveries to Industry

8-3: UCSF

8-4: UCLA

8-5: Harvard University

8-6: Stanford University

8-7: MIT

8-8: Columbia University

8-9: Washington University

8-10: University College London

8-11: Karolinska Institute

8-12: RIKEN Brain Science Institute

9-1 NeuroInsights’ 2005 Leading Neurotech Nexus Ratings

9-2 Conclusions and Policy Recommendations

10-1 Neuropharmaceutical Companies Private Profiles (status, funding, location, investment, descriptions, investors)

10-2 Neuropharmaceutical Companies Public Profiles (status, symbol, HQ, market cap revenues, description)

10-3 Neurodevice Companies Private Profiles (status, funding, location, investment, descriptions, investors)

10-4 Neurodevice Companies Public Profiles (status, symbol, HQ, market cap revenues, description)

10-5 Neurodiagnostic Companies Private Profiles (status, funding, location, investment, descriptions, investors)

10-6 Neurodiagnostic Companies Public Profiles (status, symbol, HQ, market cap revenues, description)

Abstract

The Neurotechnology Industry 2007 Report: Drugs, Devices and Diagnostics for the Brain and Nervous System is a market analysis and strategic investment guide of the global neurological disease and psychiatric illness markets. The report focuses on the more than 500 public and private companies translating advances in neuroscience into tomorrow's treatments. It provides insight and analysis of issues such as corporate financing, market activity, growth drivers and global industry conditions that make up the obstacles and opportunities facing the industry. The report provides an in-depth look at fifteen brain and central nervous system disorders, including Alzheimer's disease, addiction, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, memory decline, obesity, pain, Parkinson's, psychiatric disorders, stroke and other brain-related illnesses.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options

Search Inside Report


advertise with us

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2008